Whalesbook
Wedding Season Ka Kamaal
India mein shaadi ka season chal raha hai aur log apni wedding photos ke liye ekdum 'fit' dikhna chahte hain. Clinics bhi iska fayda utha kar GLP-1 drugs ko 'pre-wedding' packages mein promote kar rahe hain. Doctors bol rahe hain ki 20% se zyada queries toh shaadi wale couples se aa rahi hain. Mounjaro aur Wegovy jaise prescription drugs ki maang ekdum badh gayi hai. Companies jaise Eli Lilly aur Novo Nordisk bol rahi hain ki ye drugs sirf doctor ki supervision mein medical reasons (diabetes, obesity) ke liye hain, na ki sirf beauty ke liye.
Mounjaro vs Wegovy: Kaun Aage?
India mein toh Mounjaro ne toh bawaal macha diya hai! Eli Lilly ka Mounjaro launch hone ke baad hi India mein sabse zyada bikne wala drug ban gaya hai. October 2025 tak iski sales ₹100 Crore ($11.38 million) ho gayi thi. Volume mein toh ye Novo Nordisk ke Wegovy se 10 guna zyada bik raha hai. Jabki Wegovy ki sales India mein bahut kam rahi, price cuts ke baad bhi. January 2026 tak Mounjaro ki annual sales ₹746 Crore pahunch gayi, jabki Wegovy ki sirf ₹72 Crore thi. Shayad Mounjaro ka combination effect zyada faydemand hai. Novo Nordisk ne Wegovy ko sasta bhi kiya hai market mein tikne ke liye.
Generics Ka Attack Aur Regulators Ki Nazar
India mein semaglutide ka patent March 2026 mein khatam ho raha hai. Iske baad Indian drug makers Ozempic aur Wegovy ke saste generic versions launch kar denge. Kuch generics toh ₹325 per week mein milenge! Ye sabke liye access badhayega, lekin misuse aur illegal sales ka risk bhi badha dega. Isliye India ka drug regulator pharmacies aur clinics par inspections badha raha hai taaki galat practices aur jhooti advertising band ho. Warning di gayi hai ki ye drugs sirf prescription par hi milenge aur doctor ki dekhbhal mein hi use hone chahiye, cosmetic use ke liye nahi.
Company Ka Valuation Aur Future
Eli Lilly ki market value lagbhag $900 billion hai aur investors ko uske obesity aur diabetes drugs par bahut bharosa hai. Unka P/E ratio 40-43 ke aas paas hai. Dusri taraf, Novo Nordisk ki market value lagbhag $164 billion hai aur P/E ratio 10-11 ke aas paas hai, jo thoda conservative view dikhata hai. Novo Nordisk ko Mounjaro aur generics se competition ka dar hai.
Risks Aur Challenges Aage
India mein GLP-1 drugs ka badhta demand, khaas kar bina medical reason ke, bahut risky hai. Regulators iska misuse rokne ki koshish kar rahe hain, aur bina doctor ke use karne par health problems ka warning de rahe hain. Saste generics aayenge toh access badhega, par price competition aur quality concerns bhi badhenge. Novo Nordisk ke liye Mounjaro aur generics dono badi challenges hain. Eli Lilly bhi competition aur regulatory attention se nahi bach payegi. Companies ko market mein kaise compete karna hai aur price ko kaise manage karna hai, ye unke future ke liye bahut important hoga.